Pay in 4 interest-free payments of $25.50 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
Pharmacokinetic studies of dBET1 (50 mg/kg IP) corroborate adequate drug exposure in vivo (Cmax = 392 nM
Formula: C18H18N4
Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17
52-42)33-17-18-40(48
Etravirine - CAS# 269055-15-4 Catalog No.:M10765-10 Pharmacokinetic studies of dBET1 (50Etravirine, also known as TMC 125 and R 165335, is a drug used for the treatment of HIV. Etravirine is a non nucleoside reverse transcriptase inhibitor (NNRTI). It was also approved in 2008. Etravirine, in combination with other anti retrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in antiretroviral treatment experienced adult patients, who have evidence of viral replication and HIV 1 strains